Mechanisms of acetaminophen-induced liver disease

Drug-Induced Liver Disease, Second Edition

Volumn , Issue , 2007, Pages 353-388

  Nelson, Sidney D ^a   Bruschi, Sam A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85049381608     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (397)

1. Prescott LF. Paracetamol (Acetaminophen): A Critical Bibliographic Review. London: Taylor and Francis, 1996.
2. Bessems JG, Vermeulen NP. Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit Rev Toxicol 2001; 31:55-138.
3. Blakely P, McDonald BR. Acute renal failure due to acetaminophen ingestion: a case report and review of the literature. J Am Soc Nephrol 1995; 6:48-53.
4. De Broe ME, Elseviers MM. Analgesic nephropathy. N Engl J Med 1998; 338:446-52.
5. Feinstein AR, Heinemann LAJ, Curham GC, et al. Relationship between nonphenacetin combined analgesics and nephropathy: a review. Kidney Int 2000; 58:2259-64.
6. Bromer MQ, Black M. Acetaminophen hepatotoxicity. Clin Liver Dis 2003; 7:351-67.
7. Hinson JA. Biochemical toxicology of acetaminophen. Rev Biochem Toxicol 1980; 2:103-30.
8. Josephy DP. The molecular toxicology of acetaminophen. Drug Metab Rev 2005; 37:581-94.
9. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol 2002; 40:3-20.
10. Atcha Z, Majeed A. Paracetamol related deaths in England and Wales. Health Stat Q 2000; 7:5-9.
11. Gow PJ, Jones RM, Dobson JL, Angus PW. Etiology and outcome of fulminant hepatic failure managed at an Australian liver transplant unit. J Gastroenterol Hepatol 2004; 19:154-9.
12. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42:1364-72.
13. Sheen CL, Dillon JF, Bateman DN, Simpson KJ, MacDonald TM. Paracetamol-related deaths in Scotland, 1994-2000. Br J Clin Pharmacol 2002; 54:430-2.
14. Litovitz TL, Klein-Schwartz W, Dyer KS, Shannon M, Lee S, Powers M. 1997 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1998; 16:443-97.
15. Vale JA, Proudfoot AT. Paracetamol (acetaminophen) poisoning. Lancet 1995; 346:547-52.
16. Nourjah P, Ahmad SR, Karwoski C, Willy M. Estimates of acetaminophen (paracetomal)-associated overdoses in the United States. Pharmacoepidemiol Drug Saf 2006; 15:398-405.
17. Kaplowitz N. Acetaminophen hepatoxicity: what do we know, what don’t we know, and what do we do next? Hepatology 2004; 40:23-6.
18. Rumack BH. Acetaminophen misconceptions. Hepatology 2004; 40:10-15.
19. Watkins PB, Kaplowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, Harris SC. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006; 296:87-93.
20. Hawton K, Townsend E, Deeks J, Appleby L, Gunnell D, Bennewith O, Cooper J. Effects of legislation restricting pack sizes of paracetamol and salicylate on self poisoning in the United Kingdom: before and after study. Br Med J 2001; 322:1203-7.
21. Boyd EM, Bereczky GM. Liver necrosis from paracetamol. Br J Pharmacol Chemother 1966; 26:606-14.
22. Eder H. Chronic toxicity studies on phenacetin. N-acetyl-p-aminophenol (NAPA) and acetylsalicylic acid on cats. Acta Pharmacol Toxicol (Copenh) 1964; 21:197-204.
23. Davidson DG, Eastham WN. Acute liver necrosis following overdose of paracetamol. Br Med J 1966; 5512:497-9.
24. Thomson JS, Prescott LF. Liver damage and impaired glucose tolerance after paracetamol overdosage. Br Med J 1966; 5512:506-7.
25. Jollow DJ, Mitchell JR, Potter WZ, Davis DC, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther 1973; 187:195-202.
26. Mitchell JR, Jollow DJ, Potter WZ, Davis DC, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther 1973; 187:185-94.
27. Potter WZ, Davis DC, Mitchell JR, Jollow DJ, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. III. Cytochrome P-450-mediated covalent binding in vitro. J Pharmacol Exp Ther 1973; 187:203-10.
28. Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther 1973; 187:211-7.
29. Mitchell JR, Thorgeirsson SS, Potter WZ, Jollow DJ, Keiser H. Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin Pharmacol Ther 1974; 16:676-84.
30. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005; 41:1179-97.
31. Routledge P, Vale JA, Bateman DN, et al. Paracetamol (acetaminophen) poisoning. No need to change current guidelines to accident departments. Br Med J 1998; 317:1609-10.
32. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988; 319:1557-62.
33. Nelson SD. Analgesic-antipyretics. In: Levy RH et al, ed. Metabolic Drug Interactions. Philadelphia, PA: Lippincott Williams and Williams, 2000:447-55.
34. Nelson SD. Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Semin Liver Dis 1990; 10:267-78.
35. Johnson KA, Plumb R. Investigating the human metabolism of acetaminophen using UPLC and exact mass oa-TOF MS. J Pharm Biomed Anal 2005; 39:805-10.
36. Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO, Mackenzie PI. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 2001; 299:998-1006.
37. Kostrubsky SE, Sinclair JF, Strom SC, et al. Phenobarbital and phenytoin increased acetaminophen hepatotoxicity due to inhibition of UDP-glucuronosyltransferases in cultured human hepatocytes. Toxicol Sci 2005; 87:146-55.
38. Mutlib AE, Goosen TC, Bauman JN, Williams JA, Kulkarni S, Kostrubsky SE. Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen induced toxicity. Chem Res Toxicol 2006; 19:701-9.
39. Duffel MW. Sulfotransferases. In: Guengerich FP, ed. Comprehensive Toxicology, Vol. 3. Oxford:Elsevier, 1997:365-83.
40. de Morais SM, Chow SY, Wells PG. Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. Toxicol Appl Pharmacol 1992; 117:81-7.
41. Court MH, Greenblatt DJ. Molecular basis for deficient acetaminophen glucuronidation in cats. An interspecies comparison of enzyme kinetics in liver microsomes. Biochem Pharmacol 1997; 53:1041-7.
42. de Morais SM, Uetrecht JP, Wells PG. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert’s syndrome. Gastroenterology 1992; 102:577-86.
43. Rodriguez E, Regadera P. The heterogeneity of paracetamol metabolism in Gilbert’s disease. Gastroenterol Hepatol 1999; 22:265-9.
44. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317:192-7.
45. Bray GP, Harrison PM, O’Grady JG, Tredger JM, Williams R. Long-term anticonvulsant therapy worsens outcome in paracetamol-induced fulminant hepatic failure. Hum Exp Toxicol 1992; 11:265-70.
46. Lystback BB, Norregaard P. A case of paracetamol retard poisoning with fatal outcome. Ugeskr Laeger 1995; 157:899-900.
47. Minton NA, Henry JA, Frankel RJ. Fatal paracetamol poisoning in an epileptic. Hum Toxicol 1988; 7:33-4.
48. Pirotte JH. Apparent potentiation of hepatotoxicity from small doses of acetaminophen by phenobarbital. Ann Intern Med 1984; 101:403.
49. Nicholls AW, Caddick S, Wilson ID, Farrant RD, Lindon JC, Nicholson JK. High resolution NMR spectroscopic studies on the metabolism and futile deacetylation of 4-hydroxyacetanilide (paracetamol) in the rat. Biochem Pharmacol 1995; 49:1155-64.
50. Mugford CA, Tarloff JB. The contribution of oxidation and deacetylation to acetaminophen nephrotoxicity in female Sprague-Dawley rats. Toxicol Lett 1997; 93:15-22.
51. Newton JF, Kuo CH, DeShone GM, Hoefle D, Bernstein J, Hook JB. The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats. Toxicol Appl Pharmacol 1985; 81:416-30.
52. Rothen JP, Haefeli WE, Meyer UA, Todesco L, Wenk M. Acetaminophen is an inhibitor of hepatic N-acetyltransferase 2 in vitro and in vivo. Pharmacogenetics 1998; 8:553-9.
53. Dahlin DC, Miwa GT, Lu AY, Nelson SD. N-acetyl-p-benzoquinone imine: a cytochrome P-450- mediated oxidation product of acetaminophen. Proc Natl Acad Sci USA 1984; 81:1327-31.
54. Hinson JA, Pohl LR, Gillette JR. N-Hydroxyacetaminophen: a microsomal metabolite of N-hydroxyphenacetin but apparently not of acetaminophen. Life Sci 1979; 24:2133-8.
55. Nelson SD, Forte AJ, Dahlin DC. Lack of evidence for N-hydroxyacetaminophen as a reactive metabolite of acetaminophen in vitro. Biochem Pharmacol 1980; 29:1617-20.
56. Blair IA, Boobis AR, Davies DJ, Cresp TM. Paracetamol oxidation: synthesis and reactivity of N-acetyl-p-benzoquinone imine. Tetrahedron Lett 1980; 21:4947-50.
57. Dahlin DC, Nelson SD. Synthesis, decomposition kinetics, and preliminary toxicological studies of pure N-acetyl-p-benzoquinone imine, a proposed toxic metabolite of acetaminophen. J Med Chem 1982; 25:885-6.
58. Albano E, Rundgren M, Harvison PJ, Nelson SD, Moldeus P. Mechanisms of N-acetyl-p-benzoquinone imine cytotoxicity. Mol Pharmacol 1985; 28:306-11.
59. Corcoran GB, Mitchell JR, Vaishnav YN, Horning EC. Evidence that acetaminophen and N-hydroxyacetaminophen form a common arylating intermediate, N-acetyl-p-benzoquinoneimine. Mol Pharmacol 1980; 18:536-42.
60. Holme JA, Dahlin DC, Nelson SD, Dybing E. Cytotoxic effects of N-acetyl-p-benzoquinone imine, a common arylating intermediate of paracetamol and N-hydroxyparacetamol. Biochem Pharmacol 1984; 33:401-6.
61. Miner DJ, Kissinger PT. Evidence for the involvement of N-acetyl-p-quinoneimine in acetaminophen metabolism. Biochem Pharmacol 1979; 28:3285-90.
62. Hinson JA, Monks TJ, Hong M, Highet RJ, Pohl LR. 3-(glutathion-S-yl)acetaminophen: a biliary metabolite of acetaminophen. Drug Metab Dispos 1982; 10:47-50.
63. Nelson SD, Vaishnav Y, Kambara H, Baillie TA. Comparative electron impact, chemical ionization and field desorption mass spectra of some thioether metabolites of acetaminophen. Biomed Mass Spectrom 1981; 8:244-51.
64. Harvison PJ, Guengerich FP, Rashed MS, Nelson SD. Cytochrome P-450 isozyme selectivity in the oxidation of acetaminophen. Chem Res Toxicol 1988; 1:47-52.
65. Slattery JT, Wilson JM, Kalhorn TF, Nelson SD. Dose-dependent pharmacokinetics of acetaminophen:evidence of glutathione depletion in humans. Clin Pharmacol Ther 1987; 41:413-8.
66. Powis G, See KL, Santone KS, Melder DC, Hodnett EM. Quinoneimines as substrates for quinone reductase (NAD(P)H: (quinone-acceptor)oxidoreductase) and the effect of dicumarol on their cytotoxicity. Biochem Pharmacol 1987; 36:2473-9.
67. Powis G, Svingen BA, Dahlin DC, Nelson SD. Enzymatic and non-enzymatic reduction of N-acetylp- benzoquinone imine and some properties of the N-acetyl-p-benzosemiquinone imine radical. Biochem Pharmacol 1984; 33:2367-70.
68. Chen W, Shockcor JP, Tonge R, Hunter A, Gartner C, Nelson SD. Protein and nonprotein cysteinyl thiol modification by N-acetyl-p-benzoquinone imine via a novel ipso adduct. Biochemistry 1999; 38:8159-66.
69. Coles B, Wilson I, Wardman P, Hinson JA, Nelson SD, Ketterer B. The spontaneous and enzymatic reaction of N-acetyl-p-benzoquinonimine with glutathione: a stopped-flow kinetic study. Arch Biochem Biophys 1988; 264:253-60.
70. Hinson JA, Pohl LR, Monks TJ, Gillette JR, Guengerich FP. 3-Hydroxyacetaminophen: a microsomal metabolite of acetaminophen. Evidence against an epoxide as the reactive metabolite of acetaminophen. Drug Metab Dispos 1980; 8:289-94.
71. Forte AJ, Wilson JM, Slattery JT, Nelson SD. The formation and toxicity of catechol metabolites of acetaminophen in mice. Drug Metab Dispos 1984; 12:484-91.
72. Chen W. Mechanistic studies on the formation of oxidative metabolites of acetaminophen. Medicinal Chemistry. Seattle: University of Washington, 1998.
73. Chen W, Koenigs LL, Thompson SJ, Peter RM, Rettie AE, Trager WF, Nelson SD. Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirusexpressed and purified human cytochromes P450 2E1 and 2A6. Chem Res Toxicol 1998; 11:295-301.
74. Dong H, Haining RL, Thummel KE, Rettie AE, Nelson SD. Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos 2000; 28:1397-400.
75. Regal KM. Caffeine as an active site probe of cytochrome P4501A2. School of Pharmacy. Seattle:University of Washington, 1998.
76. Thummel KE, Lee CA, Kunze KL, Nelson SD, Slattery JT. Oxidation of acetaminophen to N-acetyl-paminobenzoquinone imine by human CYP3A4. Biochem Pharmacol 1993; 45:1563-9.
77. Patten CJ, Thomas PE, Guy RL, Lee M, Gonzalez FJ, Guengerich FP, Yang CS. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem Res Toxicol 1993; 6:511-8.
78. Raucy JL, Lasker JM, Lieber CS, Black M. Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch Biochem Biophys 1989; 271:270-83.
79. Anderson KE, Schneider J, Pantuck EJ, et al. Acetaminophen metabolism in subjects fed charcoalbroiled beef. Clin Pharmacol Ther 1983; 34:369-74.
80. Bock KW, Wiltfang J, Blume R, Ullrich D, Bircher J. Paracetamol as a test drug to determine glucuronide formation in man. Effects of inducers and of smoking. Eur J Clin Pharmacol 1987; 31:677-83.
81. Miners JO, Attwood J, Birkett DJ. Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen’s metabolic pathways. Clin Pharmacol Ther 1984; 35:480-6.
82. Sarich T, Kalhorn T, Magee S, et al. The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin. Clin Pharmacol Ther 1997; 62:21-8.
83. Tonge RP, Kelly EJ, Bruschi SA, Kalhorn T, Eaton DL, Nebert DW, Nelson SD. Role of CYP1A2 in the hepatotoxicity of acetaminophen: investigations using Cyp1a2 null mice. Toxicol Appl Pharmacol 1998; 153:102-8.
84. Lee SS, Buters JT, Pineau T, Fernandez-Salguero P, Gonzalez FJ. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 1996; 271:12063-7.
85. Zaher H, Buters JT, Ward JM, et al. Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. Toxicol Appl Pharmacol 1998; 152:193-9.
86. Amouyal G, Larrey D, Letteron P, Geneve J, Labbe G, Belghiti J, Pessayre D. Effects of methoxsalen on the metabolism of acetaminophen in humans. Biochem Pharmacol 1987; 36:2349-52.
87. Letteron P, Descatoire V, Larrey D, DeGott C, Tinel M, Geneve J, Pessayre D. Pre- or post-treatment with methoxsalen prevents the hepatotoxicity of acetaminophen in mice. J Pharmacol Exp Ther 1986; 239:559-67.
88. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90:11825-9.
89. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278:441-6.
90. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270:414-23.
91. Manyike PT, Kharasch ED, Kalhorn TF, Slattery JT. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin Pharmacol Ther 2000; 67:275-82.
92. Prescott LF, Howie D, Darrien I, Adriaenssens P. Paracetamol hepatotoxicity in man. In: Bundgaard H, Juul P, Kofod H, eds. Drug Design and Adverse Reactions. Cophenhagen:Munksgaard, 1977:99-108.
93. Rumack BH. Acetaminophen overdose in young children. Treatment and effects of alcohol and other additional ingestants in 417 cases. Am J Dis Child 1984; 138:428-33.
94. Miller RP, Roberts RJ, Fischer LJ. Acetaminophen elimination kinetics in neonates, children, and adults. Clin Pharmacol Ther 1976; 19:284-94.
95. Lauterburg BH, Vaishnav Y, Stillwell WG, Mitchell JR. The effects of age and glutathione depletion on hepatic glutathione turnover in vivo determined by acetaminophen probe analysis. J Pharmacol Exp Ther 1980; 213:54-8.
96. Lesko SM, Mitchell AA. The safety of acetaminophen and ibuprofen among children younger than two years old. Pediatrics 1999; 104:e39.
97. Alonso EM, Sokol RJ, Hart J, Tyson RW, Narkewicz MR, Whitington PF. Fulminant hepatitis associated with centrilobular hepatic necrosis in young children. J Pediatr 1995; 127:888-94.
98. Caravati EM. Unintentional acetaminophen ingestion in children and the potential for hepatotoxicity. J Toxicol Clin Toxicol 2000; 38:291-6.
99. Heubi JE, Barbacci MB, Zimmerman HJ. Therapeutic misadventures with acetaminophen: hepatoxicity after multiple doses in children. J Pediatr 1998; 132:22-7.
100. Hynson JL, South M. Childhood hepatotoxicity with paracetamol doses less than 150 mg/kg per day. Med J Aust 1999; 171:497.
101. Miles FK, Kamath R, Dorney SF, Gaskin KJ, O’Loughlin EV. Accidental paracetamol overdosing and fulminant hepatic failure in children. Med J Aust 1999; 171:472-5.
102. Rivera-Penera T, Gugig R, Davis J, et al. Outcome of acetaminophen overdose in pediatric patients and factors contributing to hepatotoxicity. J Pediatr 1997; 130:300-4.
103. Daly FF, Dart RC, Prescott LF. Accidental paracetamol overdosing and fulminant hepatic failure in children. Med J Aust 2000; 173:558-60.
104. Parikh S, Dillon LC, Scharf SL. Hepatotoxicity possibly due to paracetamol with carbamazepine. Intern Med J 2004; 34:441-2.
105. Wilson JT, Kasantikul V, Harbison R, Martin D. Death in an adolescent following an overdose of acetaminophen and phenobarbital. Am J Dis Child 1978; 132:466-73.
106. Wright N, Prescott LF. Potentiation by previous drug therapy of hepatotoxicity following paracetamol overdosage. Scott Med J 1973; 18:56-8.
107. Young CR, Mazure CM. Fulminant hepatic failure from acetaminophen in an anorexic patient treated with carbamazepine. J Clin Psychiatry 1998; 59:622.
108. Prescott LF, Critchley JA, Balali-Mood M, Pentland B. Effects of microsomal enzyme induction on paracetamol metabolism in man. Br J Clin Pharmacol 1981; 12:149-53.
109. Dai G, Chou N, He L, et al. Retinoid X receptor alpha regulates the expression of glutathione S-transferase genes and modulates acetaminophen-glutathione conjugation in mouse liver. Mol Pharmacol 2005; 68:1590-6.
110. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, Kliewer SA. Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 2002; 62:638-46.
111. Wu Y, Zhang X, Bardag-Gorce F, et al. Retinoid X receptor alpha regulates glutathione homeostasis and xenobiotic detoxification processes in mouse liver. Mol Pharmacol 2004; 65:550-7.
112. Zhang J, Huang W, Chua SS, Wei P, Moore DD. Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 2002; 298:422-4.
113. Guo GL, Moffit JS, Nicol CJ, et al. Enhanced acetaminophen toxicity by activation of the pregnane X receptor. Toxicol Sci 2004; 82:374-80.
114. Zhang J, Huang W, Qatanani M, Evans RM, Moore DD. The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J Biol Chem 2004; 279:49517-22.
115. Wolf KK, Wood SG, Hunt JA, Walton-Strong BW, Yasuda K, Lan L, Duan SX, Hao Q, Wrighton SA, Jeffery EH, et al. Role of the nuclear receptor pregnane X receptor in acetaminophen hepatotoxicity. Drug Metab Dispos 2005; 33:1827-36.
116. Nelson SD, Slattery JT, Thummel KE, Watkins PB. CAR unlikely to significantly modulate acetaminophen hepatotoxicity in most humans. Hepatology 2003; 38:254-7.
117. Xiong H, Turner KC, Ward ES, Jansen PL, Brouwer KL. Altered hepatobiliary disposition of acetaminophen glucuronide in isolated perfused livers from multidrug resistance-associated protein 2-deficient TR(-) rats. J Pharmacol Exp Ther 2000; 295:512-8.
118. Zamek-Gliszczynski MJ, Hoffmaster KA, Tian X, et al. Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1. Drug Metab Dispos 2005; 33:1158-65.
119. Manautou JE, de Waart DR, Kunne C, Zelcer N, Goedken M, Borst P, Elferink RO. Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. Hepatology 2005; 42:1091-8.
120. Ghanem CI, Ruiz ML, Villanueva SS, et al. Shift from biliary to urinary elimination of acetaminophen- glucuronide in acetaminophen-pretreated rats. J Pharmacol Exp Ther 2005; 315:987-95.
121. Robinson AE, Sattar H, McDowall RD, Holder AT, Powell R. Forensic toxicology of some deaths associated with the combined use of propoxyphene and acetaminophen (paracetamol). J Forensic Sci 1977; 22:708-17.
122. Peterson GR, Hostetler RM, Lehman T, Covault HP. Acute inhibition of oxidative drug metabolism by propoxyphene (Darvon). Biochem Pharmacol 1979; 28:1783-9.
123. Pond SM, Tong TG, Kaysen GA, Menke DJ, Galinsky RE, Roberts SM, Levy G. Massive intoxication with acetaminophen and propoxyphene: unexpected survival and unusual pharmacokinetics of acetaminophen. J Toxicol Clin Toxicol 1982; 19:1-16.
124. Chien JY, Peter RM, Nolan CM, et al. Influence of polymorphic N-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid. Clin Pharmacol Ther 1997; 61:24-34.
125. Zand R, Nelson SD, Slattery JT, Thummel KE, Kalhorn TF, Adams SP, Wright JM. Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin Pharmacol Ther 1993; 54:142-9.
126. Slattery JT, Nelson SD, Thummel KE. The complex interaction between ethanol and acetaminophen. Clin Pharmacol Ther 1996; 60:241-6.
127. Thummel KE, Slattery JT, Ro H, Chien JY, Nelson SD, Lown KE, Watkins PB. Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults. Clin Pharmacol Ther 2000; 67:591-9.
128. Chien JY, Thummel KE, Slattery JT. Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. Drug Metab Dispos 1997; 25:1165-75.
129. Epstein MM, Nelson SD, Slattery JT, Kalhorn TF, Wall RA, Wright JM. Inhibition of the metabolism of paracetamol by isoniazid. Br J Clin Pharmacol 1991; 31:139-42.
130. Moulding TS, Redeker AG, Kanel GC. Acetaminophen, isoniazid, and hepatic toxicity. Ann Intern Med 1991; 114:431.
131. Murphy R, Swartz R, Watkins PB. Severe acetaminophen toxicity in a patient receiving isoniazid. Ann Intern Med 1990; 113:799-800.
132. Nolan CM, Sandblom RE, Thummel KE, Slattery JT, Nelson SD. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. Chest 1994; 105:408-11.
133. McClain CJ, Kromhout JP, Peterson FJ, Holtzman JL. Potentiation of acetaminophen hepatotoxicity by alcohol. JAMA 1980; 244:251-3.
134. Seeff LB, Cuccherini BA, Zimmerman HJ, Adler E, Benjamin SB. Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure. Ann Intern Med 1986; 104:399-404.
135. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995; 22:767-73.
136. Makin A, Williams R. Paracetamol hepatotoxicity and alcohol consumption in deliberate and accidental overdose. QJM 2000; 93:341-9.
137. Prescott LF. Paracetamol, alcohol and the liver. Br J Clin Pharmacol 2000; 49:291-301.
138. Kuffner EK, Dart RC, Bogdan GM, Hill RE, Casper E, Darton L. Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2001; 161:2247-52.
139. Takahashi T, Lasker JM, Rosman AS, Lieber CS. Induction of cytochrome P-4502E1 in the human liver by ethanol is caused by a corresponding increase in encoding messenger RNA. Hepatology 1993; 17:236-45.
140. Garcia-Ruiz C, Morales A, Ballesta A, Rodes J, Kaplowitz N, Fernandez-Checa JC. Effect of chronic ethanol feeding on glutathione and functional integrity of mitochondria in periportal and perivenous rat hepatocytes. J Clin Invest 1994; 94:193-201.
141. Hirano T, Kaplowitz N, Tsukamoto H, Kamimura S, Fernandez-Checa JC. Hepatic mitochondrial glutathione depletion and progression of experimental alcoholic liver disease in rats. Hepatology 1992; 16:1423-7.
142. Zhao P, Kalhorn TF, Slattery JT. Selective mitochondrial glutathione depletion by ethanol enhances acetaminophen toxicity in rat liver. Hepatology 2002; 36:326-35.
143. Hu Y, Ingelman-Sundberg M, Lindros KO. Induction mechanisms of cytochrome P450 2E1 in liver:interplay between ethanol treatment and starvation. Biochem Pharmacol 1995; 50:155-61.
144. Lauterburg BH, Velez ME. Glutathione deficiency in alcoholics: risk factor for paracetamol hepatotoxicity. Gut 1988; 29:1153-7.
145. Lee TD, Sadda MR, Mendler MH, Bottiglieri T, Kanel G, Mato JM, Lu SC. Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis. Alcohol Clin Exp Res 2004; 28:173-81.
146. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994; 272:1840-5.
147. Zhao P, Slattery JT. Effects of ethanol dose and ethanol withdrawal on rat liver mitochondrial glutathione: implication of potentiated acetaminophen toxicity in alcoholics. Drug Metab Dispos 2002; 30:1413-7.
148. Sinclair JF, Szakacs JG, Wood SG, et al. Acetaminophen hepatotoxicity precipitated by short-term treatment of rats with ethanol and isopentanol: protection by triacetyloleandomycin. Biochem Pharmacol 2000; 59:445-54.
149. Sinclair JF, Szakacs JG, Wood SG, et al. Short-term treatment with alcohols causes hepatic steatosis and enhances acetaminophen hepatotoxicity in Cyp2e1(-/-) mice. Toxicol Appl Pharmacol 2000; 168:114-22.
150. Andrews FJ. Retroperitoneal haematoma after paracetamol increased anticoagulation. Emerg Med J 2002; 19:84-5.
151. Antlitz AM, Mead JA, Jr., Tolentino MA. Potentiation of oral anticoagulant therapy by acetaminophen. Curr Ther Res Clin Exp 1968; 10:501-7.
152. Bartle WR, Blakely JA. Potentiation of warfarin anticoagulation by acetaminophen. JAMA 1991; 265:1260.
153. Boeijinga JJ, Boerstra EE, Ris P, Breimer DD, Jeletich-Bastiaanse A. Interaction between paracetamol and coumarin anticoagulants. Lancet 1982; 1:506.
154. Gebauer MG, Nyfort-Hansen K, Henschke PJ, Gallus AS. Warfarin and acetaminophen interaction. Pharmacotherapy 2003; 23:109-12.
155. Mahé I, Bertrand N, Drouet L, et al. Paracetamol: a haemorrhagic risk factor in patients on warfarin. Br J Clin Pharmacol 2005; 59:371-4.
156. Rubin RN, Mentzer RL, Budzynski AZ. Potentiation of anticoagulant effect of warfarin by acetaminophen (Tylenol). Clin Res 1984; 32:698a.
157. Gadisseur AP, Van Der Meer FJ, Rosendaal FR. Sustained intake of paracetamol (acetaminophen) during oral anticoagulant therapy with coumarins does not cause clinically important INR changes:a randomized double-blind clinical trial. J Thromb Haemost 2003; 1:714-7.
158. Kwan D, Bartle WR, Walker SE. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999; 39:68-75.
159. Shek KL, Chan LN, Nutescu E. Warfarin-acetaminophen drug interaction revisited. Pharmacotherapy 1999; 19:1153-8.
160. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998; 279:657-62.
161. Mahé I, Caulin C, Bergmann JF. Does paracetamol (acetaminophen) potentiate the effects of oral anticoagulants? A literature review Drug Saf 2004; 27:283-352.
162. Takigawa T, Tainaka H, Mihara K, Ogata H. Inhibition of S-warfarin metabolism by nonsteroidal antiinflammatory drugs in human liver microsomes in vitro. Biol Pharm Bull 1998; 21:541-3.
163. Whyte IM, Buckley NA, Reith DM, Goodhew I, Seldon M, Dawson AH. Acetaminophen causes an increased International Normalized Ratio by reducing functional factor VII. Ther Drug Monit 2000; 22:742-8.
164. Thijssen HH, Soute BA, Vervoort LM, Claessens JG. Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. Thromb Haemost 2004; 92:797-802.
165. Nelson SD. Mechanisms of the formation and disposition of reactive metabolites that can cause acute liver injury. Drug Metab Rev 1995; 27:147-77.
166. Myers TG, Thummel KE, Kalhorn TF, Nelson SD. Preferred orientations in the binding of 4'- hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem 1994; 37:860-7.
167. Schlichting I, Berendzen J, Chu K, et al. The catalytic pathway of cytochrome p450cam at atomic resolution. Science 2000; 287:1615-22.
168. Hasemann CA, Kurumbail RG, Boddupalli SS, Peterson JA, Deisenhofer J. Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure 1995; 3:41-62.
169. Modi S, Primrose WU, Boyle JM, Gibson CF, Lian LY, Roberts GC. NMR studies of substrate binding to cytochrome P450 BM3: comparisons to cytochrome P450 cam. Biochemistry 1995; 34:8982-8.
170. Lewis DF, Bird MG, Dickins M, Lake BG, Eddershaw PJ, Tarbit MH, Goldfarb PS. Molecular modelling of human CYP2E1 by homology with the CYP102 haemoprotein domain: investigation of the interactions of substrates and inhibitors within the putative active site of the human CYP2E1 isoform. Xenobiotica 2000; 30:1-25.
171. Rashed MS, Myers TG, Nelson SD. Hepatic protein arylation, glutathione depletion, and metabolite profiles of acetaminophen and a nonhepatotoxic regioisomer, 3'-hydroxyacetanilide, in the mouse. Drug Metab Dispos 1990; 18:765-70.
172. Roberts SA, Price VF, Jollow DJ. Acetaminophen structure-toxicity studies: in vivo covalent binding of a nonhepatotoxic analog, 3-hydroxyacetanilide. Toxicol Appl Pharmacol 1990; 105:195-208.
173. Tirmenstein MA, Nelson SD. Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a nonhepatotoxic regioisomer, 3'-hydroxyacetanilide. J Biol Chem 1989; 264:9814-9.
174. Nelson SD, Pearson PG. Covalent and noncovalent interactions in acute lethal cell injury caused by chemicals. Annu Rev Pharmacol Toxicol 1990; 30:169-95.
175. Rogers LK, Valentine CJ, Szczpyka M, Smith CV. Effects of hepatotoxic doses of acetaminophen and furosemide on tissue concentrations of CoASH and CoASSG in vivo. Chem Res Toxicol 2000; 13:873-82.
176. Tirmenstein MA, Nelson SD. Acetaminophen-induced oxidation of protein thiols. Contribution of impaired thiol-metabolizing enzymes and the breakdown of adenine nucleotides. J Biol Chem 1990; 265:3059-65.
177. Hart SG, Cartun RW, Wyand DS, Khairallah EA, Cohen SD. Immunohistochemical localization of acetaminophen in target tissues of the CD-1 mouse: correspondence of covalent binding with toxicity. Fundam Appl Toxicol 1995; 24:260-74.
178. Roberts DW, Bucci TJ, Benson RW, Warbritton AR, McRae TA, Pumford NR, Hinson JA. Immunohistochemical localization and quantification of the 3-(cystein-S-yl)-acetaminophen protein adduct in acetaminophen hepatotoxicity. Am J Pathol 1991; 138:359-71.
179. Bartolone JB, Beierschmitt WP, Birge RB, Hart SG, Wyand S, Cohen SD, Khairallah EA. Selective acetaminophen metabolite binding to hepatic and extrahepatic proteins: an in vivo and in vitro analysis. Toxicol Appl Pharmacol 1989; 99:240-9.
180. Hinson JA, Roberts DW, Benson RW, Dalhoff K, Loft S, Poulsen HE. Mechanism of paracetamol toxicity. Lancet 1990; 335:732.
181. James LP, Farrar HC, Sullivan JE, et al. Measurement of acetaminophen-protein adducts in children and adolescents with acetaminophen overdoses. J Clin Pharmacol 2001; 41:846-51.
182. Muldrew KL, James LP, Coop L, McCullough SS, Hendrickson HP, Hinson JA, Mayeux PR. Determination of acetaminophen-protein adducts in mouse liver and serum and human serum after hepatotoxic doses of acetaminophen using high-performance liquid chromatography with electrochemical detection. Drug Metab Dispos 2002; 30:446-51.
183. Dietze EC, Schafer A, Omichinski JG, Nelson SD. Inactivation of glyceraldehyde-3-phosphate dehydrogenase by a reactive metabolite of acetaminophen and mass spectral characterization of an arylated active site peptide. Chem Res Toxicol 1997; 10:1097-103.
184. Hoffmann KJ, Streeter AJ, Axworthy DB, Baillie TA. Identification of the major covalent adduct formed in vitro and in vivo between acetaminophen and mouse liver proteins. Mol Pharmacol 1985; 27:566-73.
185. Potter DW, Pumford NR, Hinson JA, Benson RW, Roberts DW. Epitope characterization of acetaminophen bound to protein and nonprotein sulfhydryl groups by an enzyme-linked immunosorbent assay. J Pharmacol Exp Ther 1989; 248:182-9.
186. Streeter AJ, Dahlin DC, Nelson SD, Baillie TA. The covalent binding of acetaminophen to protein. Evidence for cysteine residues as major sites of arylation in vitro. Chem Biol Interact 1984; 48:349-66.
187. Zhou L, McKenzie BA, Eccleston ED, Jr., Srivastava SP, Chen N, Erickson RR, Holtzman JL. The covalent binding of [14C]acetaminophen to mouse hepatic microsomal proteins: the specific binding to calreticulin and the two forms of the thiol:protein disulfide oxidoreductases. Chem Res Toxicol 1996; 9:1176-82.
188. Matthews AM, Roberts DW, Hinson JA, Pumford NR. Acetaminophen-induced hepatotoxicity. Analysis of total covalent binding vs. specific binding to cysteine. Drug Metab Dispos 1996; 24:1192-6.
189. Cohen SD, Khairallah EA. Selective protein arylation and acetaminophen-induced hepatotoxicity. Drug Metab Rev 1997; 29:59-77.
190. Hinson JA, Reid AB, McCullough SS, James LP. Acetaminophen-induced hepatotoxicity: role of metabolic activation, reactive oxygen/nitrogen species, and mitochondrial permeability transition. Drug Metab Rev 2004; 36:805-22.
191. Pumford NR, Halmes NC. Protein targets of xenobiotic reactive intermediates. Annu Rev Pharmacol Toxicol 1997; 37:91-117.
192. Qiu Y, Benet LZ, Burlingame AL. Identification of the hepatic protein targets of reactive metabolites of acetaminophen in vivo in mice using two-dimensional gel electrophoresis and mass spectrometry. J Biol Chem 1998; 273:17940-53.
193. Bartolone JB, Birge RB, Bulera SJ, Bruno MK, Nishanian EV, Cohen SD, Khairallah EA. Purification, antibody production, and partial amino acid sequence of the 58-kDa acetaminophen-binding liver proteins. Toxicol Appl Pharmacol 1992; 113:19-29.
194. Pumford NR, Martin BM, Hinson JA. A metabolite of acetaminophen covalently binds to the 56 kDa selenium binding protein. Biochem Biophys Res Commun 1992; 182:1348-55.
195. Pumford NR, Halmes NC, Martin BM, Cook RJ, Wagner C, Hinson JA. Covalent binding of acetaminophen to N-10-formyltetrahydrofolate dehydrogenase in mice. J Pharmacol Exp Ther 1997; 280:501-5.
196. Lores Arnaiz S, Llesuy S, Cutrin JC, Boveris A. Oxidative stress by acute acetaminophen administration in mouse liver. Free Radic Biol Med 1995; 19:303-10.
197. Bulera SJ, Birge RB, Cohen SD, Khairallah EA. Identification of the mouse liver 44-kDa acetaminophen- binding protein as a subunit of glutamine synthetase. Toxicol Appl Pharmacol 1995; 134:313-20.
198. Gupta S, Rogers LK, Taylor SK, Smith CV. Inhibition of carbamyl phosphate synthetase-I and glutamine synthetase by hepatotoxic doses of acetaminophen in mice. Toxicol Appl Pharmacol 1997; 146:317-27.
199. Landin JS, Cohen SD, Khairallah EA. Identification of a 54-kDa mitochondrial acetaminophenbinding protein as aldehyde dehydrogenase. Toxicol Appl Pharmacol 1996; 141:299-307.
200. Halmes NC, Hinson JA, Martin BM, Pumford NR. Glutamate dehydrogenase covalently binds to a reactive metabolite of acetaminophen. Chem Res Toxicol 1996; 9:541-6.
201. Khairallah EA, Bruno MK, Hong M, Cohen SD. Cellular consequences of protein adduct formation. Toxicologist (Abs) 1995; 15:86.
202. Fountoulakis M, Berndt P, Boelsterli UA, Crameri F, Winter M, Albertini S, Suter L. Two-dimensional database of mouse liver proteins: changes in hepatic protein levels following treatment with acetaminophen or its nontoxic regioisomer 3-acetamidophenol. Electrophoresis 2000; 21:2148-61.
203. Myers TG, Dietz EC, Anderson NL, Khairallah EA, Cohen SD, Nelson SD. A comparative study of mouse liver proteins arylated by reactive metabolites of acetaminophen and its nonhepatotoxic regioisomer, 3'-hydroxyacetanilide. Chem Res Toxicol 1995; 8:403-13.
204. Qiu Y, Benet LZ, Burlingame AL. Identification of hepatic protein targets of the reactive metabolites of the nonhepatotoxic regioisomer of acetaminophen, 3'-hydroxyacetanilide, in the mouse in vivo using two-dimensional gel electrophoresis and mass spectrometry. Adv Exp Med Biol 2001; 500:663-73.
205. Porat A, Sagiv Y, Elazar Z. A 56-kDa selenium-binding protein participates in intra-Golgi protein transport. J Biol Chem 2000; 275:14457-65.
206. Gasdaska PY, Gasdaska JR, Cochran S, Powis G. Cloning and sequencing of a human thioredoxin reductase. FEBS Lett 1995; 373:5-9.
207. Gladyshev VN, Jeang KT, Stadtman TC. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc Natl Acad Sci USA 1996; 93:6146-51.
208. Luthman M, Holmgren A. Rat liver thioredoxin and thioredoxin reductase: purification and characterization. Biochemistry 1982; 21:6628-33.
209. Matthews AM, Hinson JA, Roberts DW, Pumford NR. Comparison of covalent binding of acetaminophen and the regioisomer 3'-hydroxyacetanilide to mouse liver protein. Toxicol Lett 1997; 90:77-82.
210. Tirmenstein MA, Nelson SD. Hepatotoxicity after 3'-hydroxyacetanilide administration to buthionine sulfoximine pretreated mice. Chem Res Toxicol 1991; 4:214-7.
211. Dixon MF, Dixon B, Aparicio SR, Loney DP. Experimental paracetamol-induced hepatic necrosis: a light- and electron-microscope, and histochemical study. J Pathol 1975; 116:17-29.
212. Walker RM, Racz WJ, McElligott TF. Acetaminophen-induced hepatotoxicity in mice. Lab Invest 1980; 42:181-9.
213. Burcham PC, Harman AW. Acetaminophen toxicity results in site-specific mitochondrial damage in isolated mouse hepatocytes. J Biol Chem 1991; 266:5049-54.
214. Donnelly PJ, Walker RM, Racz WJ. Inhibition of mitochondrial respiration in vivo is an early event in acetaminophen-induced hepatotoxicity. Arch Toxicol 1994; 68:110-8.
215. Katyare SS, Satav JG. Impaired mitochondrial oxidative energy metabolism following paracetamolinduced hepatotoxicity in the rat. Br J Pharmacol 1989; 96:51-8.
216. Meyers LL, Beierschmitt WP, Khairallah EA, Cohen SD. Acetaminophen-induced inhibition of hepatic mitochondrial respiration in mice. Toxicol Appl Pharmacol 1988; 93:378-87.
217. Ramsay RR, Rashed MS, Nelson SD. In vitro effects of acetaminophen metabolites and analogs on the respiration of mouse liver mitochondria. Arch Biochem Biophys 1989; 273:449-57.
218. Strubelt O, Younes M. The toxicological relevance of paracetamol-induced inhibition of hepatic respiration and ATP depletion. Biochem Pharmacol 1992; 44:163-70.
219. Vendemiale G, Grattagliano I, Altomare E, Turturro N, Guerrieri F. Effect of acetaminophen administration on hepatic glutathione compartmentation and mitochondrial energy metabolism in the rat. Biochem Pharmacol 1996; 52:1147-54.
220. Jaeschke H. Glutathione disulfide formation and oxidant stress during acetaminophen-induced hepatotoxicity in mice in vivo: the protective effect of allopurinol. J Pharmacol Exp Ther 1990; 255:935-41.
221. Martin FL, McLean AE. Adenosine triphosphate (ATP) levels in paracetamol-induced cell injury in the rat in vivo and in vitro. Toxicology 1995; 104:91-7.
222. Parmar DV, Ahmed G, Khandkar MA, Katyare SS. Mitochondrial ATPase: a target for paracetamolinduced hepatotoxicity. Eur J Pharmacol 1995; 293:225-9.
223. Burcham PC, Harman AW. Effect of acetaminophen hepatotoxicity on hepatic mitochondrial and microsomal calcium contents in mice. Toxicol Lett 1988; 44:91-9.
224. Lauterburg BH. Early disturbance of calcium translocation across the plasma membrane in toxic liver injury. Hepatology 1987; 7:1179-83.
225. Moore M, Thor H, Moore G, Nelson S, Moldeus P, Orrenius S. The toxicity of acetaminophen and N-acetyl-p-benzoquinone imine in isolated hepatocytes is associated with thiol depletion and increased cytosolic Ca2+. J Biol Chem 1985; 260:13035-40.
226. Nicotera P, Rundgren M, Porubek DJ, Cotgreave I, Moldeus P, Orrenius S, Nelson SD. On the role of Ca2+ in the toxicity of alkylating and oxidizing quinone imines in isolated hepatocytes. Chem Res Toxicol 1989; 2:46-50.
227. Tsokos-Kuhn JO, Todd EL, McMillin-Wood JB, Mitchell JR. ATP-dependent calcium uptake by rat liver plasma membrane vesicles. Effect of alkylating hepatotoxins in vivo. Mol Pharmacol 1985; 28:56-61.
228. Corcoran GB, Chung SJ, Salazar DE. Early inhibition of the Na+/K+-ATPase ion pump during acetaminophen-induced hepatotoxicity in rat. Biochem Biophys Res Commun 1987; 149:203-7.
229. Bruno MK, Khairallah EA, Cohen SD. Inhibition of protein phosphatase activity and changes in protein phosphorylation following acetaminophen exposure in cultured mouse hepatocytes. Toxicol Appl Pharmacol 1998; 153:119-32.
230. Labadarios D, Davis M, Portmann B, Williams R. Paracetamol-induced hepatic necrosis in the mouse-relationship between covalent binding, hepatic glutathione depletion and the protective effect of alpha-mercaptopropionylglycine. Biochem Pharmacol 1977; 26:31-5.
231. Nelson SD, Tirmenstein MA, Rashed MS, Myers TG. Acetaminophen and protein thiol oxidation. In: Witmer CM et al, ed. Biological Reactive Intermediates IV. New York: Plenum, 1991:579-88.
232. Tee LB, Boobis AR, Huggett AC, Davies DS. Reversal of acetaminophen toxicity in isolated hamster hepatocytes by dithiothreitol. Toxicol Appl Pharmacol 1986; 83:294-314.
233. Lauterburg BH, Smith CV, Hughes H, Mitchell JR. Biliary excretion of glutathione and glutathione disulfide in the rat. Regulation and response to oxidative stress. J Clin Invest 1984; 73:124-33.
234. Smith CV. Correlations and apparent contradictions in assessment of oxidant stress status in vivo. Free Radic Biol Med 1991; 10:217-24.
235. Smith CV, Mitchell JR. Acetaminophen hepatotoxicity in vivo is not accompanied by oxidant stress. Biochem Biophys Res Commun 1985; 133:329-36.
236. Amimoto T, Matsura T, Koyama SY, Nakanishi T, Yamada K, Kajiyama G. Acetaminophen-induced hepatic injury in mice: the role of lipid peroxidation and effects of pretreatment with coenzyme and alpha-tocopherol. Free Radic Biol Med 1995; 19:169-76.
237. Fairhurst S, Barber DJ, Clark B, Horton AA. Studies on paracetamol-induced lipid peroxidation. Toxicology 1982; 23:249-59.
238. Wendel A, Feuerstein S, Konz KH. Acute paracetamol intoxication of starved mice leads to lipid peroxidation in vivo. Biochem Pharmacol 1979; 28:2051-5.
239. Burk RF, Lane JM. Ethane production and liver necrosis in rats after administration of drugs and other chemicals. Toxicol Appl Pharmacol 1979; 50:467-78.
240. Kamiyama T, Sato C, Liu J, Tajiri K, Miyakawa H, Marumo F. Role of lipid peroxidation in acetaminophen-induced hepatotoxicity: comparison with carbon tetrachloride. Toxicol Lett 1993; 66:7-12.
241. Morrow JD, Awad JA, Kato T, Takahashi K, Badr KF, Roberts LJ, II, Burk RF. Formation of novel noncyclooxygenase- derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation. J Clin Invest 1992; 90:2502-7.
242. Walker RM, Massey TE, McElligott TF, Racz WJ. Acetaminophen toxicity in fed and fasted mice. Can J Physiol Pharmacol 1982; 60:399-404.
243. Morrow JD, Chen Y, Brame CJ, et al. The isoprostanes: unique prostaglandin-like products of freeradical- initiated lipid peroxidation. Drug Metab Rev 1999; 31:117-39.
244. Gupta S, Rogers LK, Smith CV. Biliary excretion of lysosomal enzymes, iron, and oxidized protein in Fischer-344 and Sprague-Dawley rats and the effects of diquat and acetaminophen. Toxicol Appl Pharmacol 1994; 125:42-50.
245. Gibson JD, Pumford NR, Samokyszyn VM, Hinson JA. Mechanism of acetaminophen-induced hepatotoxicity: covalent binding versus oxidative stress. Chem Res Toxicol 1996; 9:580-5.
246. Schnellmann JG, Pumford NR, Kusewitt DF, Bucci TJ, Hinson JA. Deferoxamine delays the development of the hepatotoxicity of acetaminophen in mice. Toxicol Lett 1999; 106:79-88.
247. Younes M, Sause C, Siegers CP, Lemoine R. Effect of deferrioxamine and diethyldithiocarbamate on paracetamol-induced hepato- and nephrotoxicity. The role of lipid peroxidation. J Appl Toxicol 1988; 8:261-5.
248. Younes M, Siegers CP. The role of iron in the paracetamol- and CCl4-induced lipid peroxidation and hepatotoxicity. Chem Biol Interact 1985; 55:327-34.
249. ElSisi AE, Hall P, Sim WL, Earnest DL, Sipes IG. Characterization of vitamin A potentiation of carbon tetrachloride-induced liver injury. Toxicol Appl Pharmacol 1993; 119:280-8.
250. Laskin DL. Sinusoidal lining cells and hepatotoxicity. Toxicol Pathol 1996; 24:112-8.
251. Nakae D, Yamamoto K, Yoshiji H, Kinugasa T, Maruyama H, Farber JL, Konishi Y. Liposomeencapsulated superoxide dismutase prevents liver necrosis induced by acetaminophen. Am J Pathol 1990; 136:787-95.
252. Harvison PJ, Egan RW, Gale PH, Christian GD, Hill BS, Nelson SD. Acetaminophen and analogs as cosubstrates and inhibitors of prostaglandin H synthase. Chem Biol Interact 1988; 64:251-66.
253. Potter DW, Hinson JA. The 1- and 2-electron oxidation of acetaminophen catalyzed by prostaglandin H synthase. J Biol Chem 1987; 262:974-80.
254. Potter DW, Miller DW, Hinson JA. Identification of acetaminophen polymerization products catalyzed by horseradish peroxidase. J Biol Chem 1985; 260:12174-80.
255. West PR, Harman LS, Josephy PD, Mason RP. Acetaminophen: enzymatic formation of a transient phenoxyl free radical. Biochem Pharmacol 1984; 33:2933-6.
256. Fischer V, West PR, Nelson SD, Harvison PJ, Mason RP. Formation of 4-aminophenoxyl free radical from the acetaminophen metabolite N-acetyl-p-benzoquinone imine. J Biol Chem 1985; 260:11446-50.
257. Bisby RH, Tabassum N. Properties of the radicals formed by one-electron oxidation of acetaminophen- a pulse radiolysis study. Biochem Pharmacol 1988; 37:2731-8.
258. Keller RJ, Hinson JA. Mechanism of acetaminophen-stimulated NADPH oxidation catalyzed by the peroxidase-H2O2 system. Drug Metab Dispos 1991; 19:184-7.
259. Ross D, Albano E, Nilsson U, Moldeus P. Thiyl radicals-formation during peroxidase-catalyzed metabolism of acetaminophen in the presence of thiols. Biochem Biophys Res Commun 1984; 125:109-15.
260. van de Straat R, de Vries J, Vermeulen NP. Role of hepatic microsomal and purified cytochrome P-450 in one-electron reduction of two quinone imines and concomitant reduction of molecular oxygen. Biochem Pharmacol 1987; 36:613-9.
261. Senter PD, Al-Abed Y, Metz CN, et al. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc Natl Acad Sci USA 2002; 99:144-9.
262. Jaeschke H, Knight TR, Bajt ML. The role of oxidant stress and reactive nitrogen species in acetaminophen hepatotoxicity. Toxicol Lett 2003; 144:279-88.
263. James LP, Mayeux PR, Hinson JA. Acetaminophen-induced hepatotoxicity. Drug Metab Dispos 2003; 31:1499-506.
264. Knight TR, Ho YS, Farhood A, Jaeschke H. Peroxynitrite is a critical mediator of acetaminophen hepatotoxicity in murine livers: protection by glutathione. J Pharmacol Exp Ther 2002; 303:468-75.
265. Bruschi SA. Methods and approaches to study metabolism and toxicity of acetaminophen. In: Lash LH, ed. Drug Metabolism and Transport. Molecular Methods and Mechanisms. Totowa, NJ:Humana, 2005:387.
266. Gonzalez FJ. The use of gene knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis. Toxicol Lett 2001; 120:199-208.
267. Mokhlesi B, Leikin JB, Murray P, Corbridge TC. Adult toxicology in critical care: part II: specific poisonings. Chest 2003; 123:897-922.
268. O’Grady JG. Broadening the view of acetaminophen hepatotoxicity. Hepatology 2005; 42:1252-4.
269. Schmidt LE, Dalhoff K. Serum phosphate is an early predictor of outcome in severe acetaminopheninduced hepatotoxicity. Hepatology 2002; 36:659-65.
270. Heinloth AN, Irwin RD, Boorman GA, et al. Gene expression profiling of rat livers reveals indicators of potential adverse effects. Toxicol Sci 2004; 80:193-202.
271. Adams ML, Pierce RH, Vail ME, et al. Enhanced acetaminophen hepatotoxicity in transgenic mice overexpressing BCL-2. Mol Pharmacol 2001; 60:907-15.
272. Freeman K. From point B to point A: applying toxicogenomics to biological inference. Environ Health Perspect 2005; 113:A388-93.
273. Kitteringham NR, Powell H, Jenkins RE, et al. Protein expression profiling of glutathione S-transferase pi null mice as a strategy to identify potential markers of resistance to paracetamolinduced toxicity in the liver. Proteomics 2003; 3:191-207.
274. Ruepp SU, Tonge RP, Shaw J, Wallis N, Pognan F. Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. Toxicol Sci 2002; 65:135-50.
275. Welch KD, Wen B, Goodlett DR, et al. Proteomic identification of potential susceptibility factors in drug-induced liver disease. Chem Res Toxicol 2005; 18:924-33.
276. Zhu JH, Lei XG. Double null of selenium-glutathione peroxidase-1 and copper, zinc-superoxide dismutase enhances resistance of mouse primary hepatocytes to acetaminophen toxicity. Exp Biol Med (Maywood) 2006; 231:545-52.
277. Yamamoto T, Kikkawa R, Yamada H, Horii I. Investigation of proteomic biomarkers in in vivo hepatotoxicity study of rat liver: toxicity differentiation in hepatotoxicants. J Toxicol Sci 2006; 31:49-60.
278. Ho HK, White CC, Fernandez C, Fausto N, Kavanagh TJ, Nelson SD, Bruschi SA. Nrf2 activation involves an oxidative-stress independent pathway in tetrafluoroethylcysteine-induced cytotoxicity. Toxicol Sci 2005; 86:354-64.
279. Suntres ZE. Role of antioxidants in paraquat toxicity. Toxicology 2002; 180:65-77.
280. Devalia JL, McLean AE. Covalent binding and the mechanism of paracetamol toxicity. Biochem Pharmacol 1983; 32:2602-3.
281. Devalia JL, Ogilvie RC, McLean AE. Dissociation of cell death from covalent binding of paracetamol by flavones in a hepatocyte system. Biochem Pharmacol 1982; 31:3745-9.
282. Streeter AJ, Bjorge SM, Axworthy DB, Nelson SD, Baillie TA. The microsomal metabolism and site of covalent binding to protein of 3'-hydroxyacetanilide, a nonhepatotoxic positional isomer of acetaminophen. Drug Metab Dispos 1984; 12:565-76.
283. Nelson SD, Bruschi S. Mechanisms of acetaminophen-induced liver disease. In: Kaplowitz N, DeLeve LD, eds. Drug Induced Liver Disease. 1st ed. New York: Marcel Dekker, 2003:773.
284. Hara MR, Thomas B, Cascio MB, et al. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci USA 2006; 103:3887-9.
285. Hara MR, Agrawal N, Kim SF, et al. S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. Nat Cell Biol 2005; 7:665-74.
286. Sirover MA. New insights into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochim Biophys Acta 1999; 1432:159-84.
287. Gerson RJ, Casini A, Gilfor D, Serroni A, Farber JL. Oxygen-mediated cell injury in the killing of cultured hepatocytes by acetaminophen. Biochem Biophys Res Commun 1985; 126:1129-37.
288. Kyle ME, Miccadei S, Nakae D, Farber JL. Superoxide dismutase and catalase protect cultured hepatocytes from the cytotoxicity of acetaminophen. Biochem Biophys Res Commun 1987; 149:889-96.
289. Mirochnitchenko O, Weisbrot-Lefkowitz M, Reuhl K, Chen L, Yang C, Inouye M. Acetaminophen toxicity. Opposite effects of two forms of glutathione peroxidase. J Biol Chem 1999; 274:10349-55.
290. Boobis AR, Seddon CE, Nasseri-Sina P, Davies DS. Evidence for a direct role of intracellular calcium in paracetamol toxicity. Biochem Pharmacol 1990; 39:1277-81.
291. Farber JL. The biochemical pathology of toxic cell death. Monogr Pathol 1985;19-31.
292. Tirmenstein MA, Nelson SD. Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a nonhepatotoxic regioisomer, 3'-hydroxyacetanilide, in mouse liver. J Biol Chem 1989; 264:9814-9.
293. Bruschi SA, Priestly BG. Implications of alterations in intracellular calcium ion homeostasis in the advent of paracetamol-induced cytotoxicity in primary mouse hepatocyte cultures. Toxicol In Vitro 1990; 4:743-9.
294. Coen M, Lenz EM, Nicholson JK, Wilson ID, Pognan F, Lindon JC. An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR spectroscopy. Chem Res Toxicol 2003; 16:295-303.
295. Coen M, Ruepp SU, Lindon JC, Nicholson JK, Pognan F, Lenz EM, Wilson ID. Integrated application of transcriptomics and metabonomics yields new insight into the toxicity due to paracetamol in the mouse. J Pharm Biomed Anal 2004; 35:93-105.
296. Welch KD, Reilly TP, Bourdi M, et al. Genomic identification of potential risk factors during acetaminophen-induced liver disease in susceptible and resistant strains of mice. Chem Res Toxicol 2006; 19:223-33.
297. Clayton TA, Lindon JC, Cloarec O, et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006; 440:1073-7.
298. Kikkawa R, Fujikawa M, Yamamoto T, Hamada Y, Yamada H, Horii I. In vivo hepatotoxicity study of rats in comparison with in vitro hepatotoxicity screening system. J Toxicol Sci 2006; 31:23-34.
299. Minami K, Saito T, Narahara M, et al. Relationship between hepatic gene expression profiles and hepatotoxicity in five typical hepatotoxicant-administered rats. Toxicol Sci 2005; 87:296-305.
300. Reilly TP, Bourdi M, Brady JN, Pise-Masison CA, Radonovich MF, George JW, Pohl LR. Expression profiling of acetaminophen liver toxicity in mice using microarray technology. Biochem Biophys Res Commun 2001; 282:321-8.
301. Tolson JK, Dix DJ, Voellmy RW, Roberts SM. Increased hepatotoxicity of acetaminophen in Hsp70i knockout mice. Toxicol Appl Pharmacol 2006; 210:157-62.
302. Williams DP, Garcia-Allan C, Hanton G, et al. Time course toxicogenomic profiles in CD-1 mice after nontoxic and nonlethal hepatotoxic paracetamol administration. Chem Res Toxicol 2004; 17:1551-61.
303. Yamamoto T, Kikkawa R, Yamada H, Horii I. Identification of oxidative stress-related proteins for predictive screening of hepatotoxicity using a proteomic approach. J Toxicol Sci 2005; 30:213-27.
304. Gujral JS, Knight TR, Farhood A, Bajt ML, Jaeschke H. Mode of cell death after acetaminophen overdose in mice: apoptosis or oncotic necrosis? Toxicol Sci 2002; 67:322-8.
305. El-Hassan H, Anwar K, Macanas-Pirard P, et al. Involvement of mitochondria in acetaminopheninduced apoptosis and hepatic injury: roles of cytochrome c, Bax, Bid, and caspases. Toxicol Appl Pharmacol 2003; 191:118-29.
306. Macanas-Pirard P, Yaacob NS, Lee PC, Holder JC, Hinton RH, Kass GE. Glycogen synthase kinase-3 mediates acetaminophen-induced apoptosis in human hepatoma cells. J Pharmacol Exp Ther 2005; 313:780-9.
307. Bajt ML, Lemasters JJ, Jaeschke H. Role of mitochondrial acetaminophen bax translocation in acetaminophen-induced hepatic necrosis in mice. Society of Toxicology. New Orleans: Oxford University Press, 2005.
308. Bassik MC, Scorrano L, Oakes SA, Pozzan T, Korsmeyer SJ. Phosphorylation of BCL-2 regulates ER Ca2+ homeostasis and apoptosis. EMBO J 2004; 23:1207-16.
309. Oakes SA, Scorrano L, Opferman JT, Bassik MC, Nishino M, Pozzan T, Korsmeyer SJ. Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum. Proc Natl Acad Sci USA 2005; 102:105-10.
310. Scorrano L, Oakes SA, Opferman JT, Cheng EH, Sorcinelli MD, Pozzan T, Korsmeyer SJ. BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science 2003; 300:135-9.
311. Sawada M, Hayes P, Matsuyama S. Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70. Nat Cell Biol 2003; 5:352-7.
312. Sawada M, Sun W, Hayes P, Leskov K, Boothman DA, Matsuyama S. Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat Cell Biol 2003; 5:320-9.
313. Yoshida T, Tomioka I, Nagahara T, Holyst T, Sawada M, Hayes P, Gama V, Okuno M, Chen Y, Abe Y, et al. Bax-inhibiting peptide derived from mouse and rat Ku70. Biochem Biophys Res Commun 2004; 321:961-6.
314. Guo B, Zhai D, Cabezas E, Welsh K, Nouraini S, Satterthwait AC, Reed JC. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 2003; 423:456-61.
315. Zhai D, Luciano F, Zhu X, Guo B, Satterthwait AC, Reed JC. Humanin binds and nullifies Bid activity by blocking its activation of Bax and Bak. J Biol Chem 2005; 280:15815-24.
316. Chae HJ, Kim HR, Xu C, Bailly-Maitre B, Krajewska M, Krajewski S, Banares S, Cui J, Digicaylioglu M, Ke N, et al. BI-1 regulates an apoptosis pathway linked to endoplasmic reticulum stress. Mol Cell 2004; 15:355-66.
317. Huckelhoven R. BAX Inhibitor-1, an ancient cell death suppressor in animals and plants with prokaryotic relatives. Apoptosis 2004; 9:299-307.
318. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435:677-81.
319. Bernardi P. The permeability transition pore. Control points of a cyclosporin A-sensitive mitochondrial channel involved in cell death. Biochim Biophys Acta 1996; 1275:5-9.
320. Bouchier-Hayes L, Lartigue L, Newmeyer DD. Mitochondria: pharmacological manipulation of cell death. J Clin Invest 2005; 115:2640-7.
321. Kon K, Kim JS, Jaeschke H, Lemasters JJ. Mitochondrial permeability transition in acetaminopheninduced necrosis and apoptosis of cultured mouse hepatocytes. Hepatology 2004; 40:1170-9.
322. Masubuchi Y, Suda C, Horie T. Involvement of mitochondrial permeability transition in acetaminophen- induced liver injury in mice. J Hepatol 2005; 42:110-6.
323. Reid AB, Kurten RC, McCullough SS, Brock RW, Hinson JA. Mechanisms of acetaminopheninduced hepatotoxicity: role of oxidative stress and mitochondrial permeability transition in freshly isolated mouse hepatocytes. J Pharmacol Exp Ther 2005; 312:509-16.
324. Haouzi D, Cohen I, Vieira HL, et al. Mitochondrial permeability transition as a novel principle of hepatorenal toxicity in vivo. Apoptosis 2002; 7:395-405.
325. Fiorucci S, Antonelli E, Distrutti E, Mencarelli A, Farneti S, Del Soldato P, Morelli A. Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice. Br J Pharmacol 2004; 143:33-42.
326. Basso E, Fante L, Fowlkes J, Petronilli V, Forte MA, Bernardi P. Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D. J Biol Chem 2005; 280:18558-61.
327. Baines CP, Kaiser RA, Purcell NH, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005; 434:658-62.
328. Schinzel AC, Takeuchi O, Huang Z, et al. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc Natl Acad Sci USA 2005; 102:12005-10.
329. Nakagawa T, Shimizu S, Watanabe T, et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005; 434:652-8.
330. Lavrik IN, Golks A, Krammer PH. Caspases: pharmacological manipulation of cell death. J Clin Invest 2005; 115:2665-72.
331. Jaeschke H, Cover C, Bajt ML. Role of caspases in acetaminophen-induced liver injury. Life Sci 2006; 78:1670-6.
332. Pierce RH, Franklin CC, Campbell JS, et al. Cell culture model for acetaminophen-induced hepatocyte death in vivo. Biochem Pharmacol 2002; 64:413-24.
333. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts:requirement for dATP and cytochrome c. Cell 1996; 86:147-57.
334. Leist M, Single B, Castoldi AF, Kuhnle S, Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 1997; 185:1481-6.
335. Kroemer G, El-Deiry WS, Golstein P, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ 2005; 12(Suppl. 2):1463-7.
336. Goldring CE, Kitteringham NR, Elsby R, et al. Activation of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice. Hepatology 2004; 39:1267-76.
337. Ruepp S, Boess F, Suter L, et al. Assessment of hepatotoxic liabilities by transcript profiling. Toxicol Appl Pharmacol 2005; 207:161-70.
338. Bae MA, Pie JE, Song BJ. Acetaminophen induces apoptosis of C6 glioma cells by activating the c-Jun NH(2)-terminal protein kinase-related cell death pathway. Mol Pharmacol 2001; 60:847-56.
339. Gunawan BK, Liu ZX, Han D, Hanawa N, Gaarde WA, Kaplowitz N. c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology 2006; 131:165-78.
340. Napirei M, Basnakian AG, Apostolov EO, Mannherz HG. Deoxyribonuclease 1 aggravates acetaminophen-induced liver necrosis in male CD-1 mice. Hepatology 2006; 43:297-305.
341. Jaeschke H, Bajt ML. Intracellular signaling mechanisms of acetaminophen-induced liver cell death. Toxicol Sci 2006; 89:31-41.
342. Bajt ML, Cover C, Lemasters JJ, Jaeschke H. Nuclear translocation of endonuclease G and apptosisinducing factor during acetaminophen hepatotoxicity. Society of Toxicology. San DIego: Oxford University Press, 2006.
343. Fujita T, Shirasawa T, Maruyama N. Expression and structure of senescence marker protein-30 (SMP30) and its biological significance. Mech Ageing Dev 1999; 107:271-80.
344. Fujita T. Senescence marker protein-30 (SMP30): structure and biological function. Biochem Biophys Res Commun 1999; 254:1-4.
345. Fujita T, Inoue H, Kitamura T, Sato N, Shimosawa T, Maruyama N. Senescence marker protein-30 (SMP30) rescues cell death by enhancing plasma membrane Ca(2+)-pumping activity in Hep G2 cells. Biochem Biophys Res Commun 1998; 250:374-80.
346. Matsuyama S, Kitamura T, Enomoto N, et al. Senescence marker protein-30 regulates Akt activity and contributes to cell survival in Hep G2 cells. Biochem Biophys Res Commun 2004; 321:386-90.
347. Kondo Y, Inai Y, Sato Y, et al. Senescence marker protein 30 functions as gluconolactonase in L-ascorbic acid biosynthesis, and its knockout mice are prone to scurvy. Proc Natl Acad Sci USA 2006; 103:5723-8.
348. Kondo Y, Ishigami A, Kubo S, et al. Senescence marker protein-30 is a unique enzyme that hydrolyzes diisopropyl phosphorofluoridate in the liver. FEBS Lett 2004; 570:57-62.
349. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS. Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 2005; 6:150-66.
350. Hinson JA, Pike SL, Pumford NR, Mayeux PR. Nitrotyrosine-protein adducts in hepatic centrilobular areas following toxic doses of acetaminophen in mice. Chem Res Toxicol 1998; 11:604-7.
351. Kim SF, Huri DA, Snyder SH. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 2005; 310:1966-70.
352. Cover C, Fickert P, Knight TR, Fuchsbichler A, Farhood A, Trauner M, Jaeschke H. Pathophysiological role of poly(ADP-ribose) polymerase (PARP) activation during acetaminophen-induced liver cell necrosis in mice. Toxicol Sci 2005; 84:201-8.
353. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004; 18:1272-82.
354. DeLeve LD, Wang X, Kaplowitz N, Shulman HM, Bart JA, van der Hoek A. Sinusoidal endothelial cells as a target for acetaminophen toxicity. Direct action versus requirement for hepatocyte activation in different mouse strains. Biochem Pharmacol 1997; 53:1339-45.
355. Kofman AV, Morgan G, Kirschenbaum A, Osbeck J, Hussain M, Swenson S, Theise ND. Dose- and time-dependent oval cell reaction in acetaminophen-induced murine liver injury. Hepatology 2005; 41:1252-61.
356. Donahower B, McCullough SS, Kurten RC, Lamps LW, Simpson PM, Hinson JA, James LP. Vascular endothelial growth factor and hepatocyte regeneration in acetaminophen toxicity. Am J Physiol Gastrointest Liver Physiol 2006; 291:102-9.
357. Klionsky DJ. The molecular machinery of autophagy: unanswered questions. J Cell Sci 2005; 118:7-18.
358. Levine B, Yuan J. Autophagy in cell death: an innocent convict? J Clin Invest 2005; 115:2679-88.
359. Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science 2004; 306:990-5.
360. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, Levine B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999; 402:672-6.
361. Pattingre S, Tassa A, Qu X, et al. Bcl-2 antiapoptotic proteins inhibit beclin 1-dependent autophagy. Cell 2005; 122:927-39.
362. Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, Thompson CB, Tsujimoto Y. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol 2004; 6:1221-8.
363. Boya P, Gonzalez-Polo RA, Casares N, et al. Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 2005; 25:1025-40.
364. Edinger AL, Thompson CB. Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 2004; 16:663-9.
365. Elmore SP, Qian T, Grissom SF, Lemasters JJ. The mitochondrial permeability transition initiates autophagy in rat hepatocytes. FASEB J 2001; 15:2286-7.
366. Lemasters JJ, Qian T, He L, Kim JS, Elmore SP, Cascio WE, Brenner DA. Role of mitochondrial inner membrane permeabilization in necrotic cell death, apoptosis, and autophagy. Antioxid Redox Signal 2002; 4:769-81.
367. Yu L, Wan F, Dutta S, et al. Autophagic programmed cell death by selective catalase degradation. Proc Natl Acad Sci USA 2006; 103:4952-7.
368. Massey AC, Kaushik S, Sovak G, Kiffin R, Cuervo AM. Consequences of the selective blockage of chaperone-mediated autophagy. Proc Natl Acad Sci USA 2006; 103:5805-10.
369. Snapp EL, Hegde RS, Francolini M, et al. Formation of stacked ER cisternae by low affinity protein interactions. J Cell Biol 2003; 163:257-69.
370. Davern TJ, II, James LP, Hinson JA, et al. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 2006; 130:687-94.
371. Limaye PB, Apte UM, Shankar K, Bucci TJ, Warbritton A, Mehendale HM. Calpain released from dying hepatocytes mediates progression of acute liver injury induced by model hepatotoxicants. Toxicol Appl Pharmacol 2003; 191:211-26.
372. Dambach DM, Durham SK, Laskin JD, Laskin DL. Distinct roles of NF-kappaB p50 in the regulation of acetaminophen-induced inflammatory mediator production and hepatotoxicity. Toxicol Appl Pharmacol 2006; 211:157-65.
373. Dambach DM, Watson LM, Gray KR, Durham SK, Laskin DL. Role of CCR2 in macrophage migration into the liver during acetaminophen-induced hepatotoxicity in the mouse. Hepatology 2002; 35:1093-103.
374. Marshall E. Clinical medicine. Accident prompts a closer look at antibody trials. Science 2006; 312:172.
375. James MJ, Cleland LG. Cyclooxygenase-2 inhibitors: what went wrong? Curr Opin Clin Nutr Metab Care 2006; 9:89-94.
376. Blazka ME, Germolec DR, Simeonova P, Bruccoleri A, Pennypacker KR, Luster MI. Acetaminopheninduced hepatotoxicity is associated with early changes in NF-kB and NF-IL6 DNA binding activity. J Inflamm 1995; 47:138-50.
377. Blazka ME, Wilmer JL, Holladay SD, Wilson RE, Luster MI. Role of proinflammatory cytokines in acetaminophen hepatotoxicity. Toxicol Appl Pharmacol 1995; 133:43-52.
378. Ishida Y, Kondo T, Tsuneyama K, Lu P, Takayasu T, Mukaida N. The pathogenic roles of tumor necrosis factor receptor p55 in acetaminophen-induced liver injury in mice. J Leukoc Biol 2004; 75:59-67.
379. Gardner CR, Laskin JD, Dambach DM, et al. Exaggerated hepatotoxicity of acetaminophen in mice lacking tumor necrosis factor receptor-1. Potential role of inflammatory mediators. Toxicol Appl Pharmacol 2003; 192:119-30.
380. Chiu H, Gardner CR, Dambach DM, Brittingham JA, Durham SK, Laskin JD, Laskin DL. Role of p55 tumor necrosis factor receptor 1 in acetaminophen-induced antioxidant defense. Am J Physiol Gastrointest Liver Physiol 2003; 285:G959-66.
381. Bernal W, Donaldson P, Underhill J, Wendon J, Williams R. Tumor necrosis factor genomic polymorphism and outcome of acetaminophen (paracetamol)-induced acute liver failure. J Hepatol 1998; 29:53-9.
382. Boess F, Bopst M, Althaus R, Polsky S, Cohen SD, Eugster HP, Boelsterli UA. Acetaminophen hepatotoxicity in tumor necrosis factor/lymphotoxin-alpha gene knockout mice. Hepatology 1998; 27:1021-9.
383. Blazka ME, Elwell MR, Holladay SD, Wilson RE, Luster MI. Histopathology of acetaminopheninduced liver changes: role of interleukin 1 alpha and tumor necrosis factor alpha. Toxicol Pathol 1996; 24:181-9.
384. Bourdi M, Masubuchi Y, Reilly TP, et al. Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology 2002; 35:289-98.
385. Hogaboam CM, Simpson KJ, Chensue SW, et al. Macrophage inflammatory protein-2 gene therapy attenuates adenovirus- and acetaminophen-mediated hepatic injury. Gene Ther 1999; 6:573-84.
386. Hogaboam CM, Bone-Larson CL, Steinhauser ML, et al. Novel CXCR2-dependent liver regenerative qualities of ELR-containing CXC chemokines. FASEB J 1999; 13:1565-74.
387. Liu J, Li C, Waalkes MP, Clark J, Myers P, Saavedra JE, Keefer LK. The nitric oxide donor, V-PYRRO/NO, protects against acetaminophen-induced hepatotoxicity in mice. Hepatology 2003; 37:324-33.
388. Gardner CR, Laskin JD, Dambach DM, et al. Reduced hepatotoxicity of acetaminophen in mice lacking inducible nitric oxide synthase: potential role of tumor necrosis factor-alpha and interleukin-10. Toxicol Appl Pharmacol 2002; 184:27-36.
389. Hinson JA, Bucci TJ, Irwin LK, Michael SL, Mayeux PR. Effect of inhibitors of nitric oxide synthase on acetaminophen-induced hepatotoxicity in mice. Nitric Oxide 2002; 6:160-7.
390. Michael SL, Mayeux PR, Bucci TJ, Warbritton AR, Irwin LK, Pumford NR, Hinson JA. Acetaminophen- induced hepatotoxicity in mice lacking inducible nitric oxide synthase activity. Nitric Oxide 2001; 5:432-41.
391. Zhang H, Cook J, Nickel J, Yu R, Stecker K, Myers K, Dean NM. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol 2000; 18:862-7.
392. Boulares AH, Giardina C, Inan MS, Khairallah EA, Cohen SD. Acetaminophen inhibits NF-kappaB activation by interfering with the oxidant signal in murine Hepa 1-6 cells. Toxicol Sci 2000; 55:370-5.
393. Joshi GP. NCX-701. NicOx. Curr Opin Investig Drugs 2004; 5:755-9.
394. Fiorucci S, Antonelli E, Mencarelli A, et al. A NO-releasing derivative of acetaminophen spares the liver by acting at several checkpoints in the fas pathway. Br J Pharmacol 2002; 135:589-99.
395. Moore PK, Marshall M. Nitric oxide releasing acetaminophen (nitroacetaminophen). Dig Liver Dis 2003; 35(Suppl. 2):S49-60.
396. Lyons L, Studdiford JS, Sommaripa AM. Treatment of acetaminophen overdosage with N-acetylcysteine. N Engl J Med 1977; 296:174-5.
397. Piperno E, Berssenbruegge DA. Reversal of experimental paracetamol toxicosis with N-acetylcysteine. Lancet 1976; 2:738-9.